| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: the ANSWER cohort study. |
| 掲載誌名 | 正式名：Joint bone spine 略 称：Joint Bone Spine ISSNコード：17787254/1297319X |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.Online ahead of print |
| 著者・共著者 | Yuki Etani, Yasutaka Okita, Yuichi Maeda, Kohei Tsujimoto, Takaaki Noguchi, Ryu Watanabe, Motomu Hashimoto, Iku Shirasugi, Naoki Nakano, Yuji Nozaki, Chisato Ashida, Yonsu Son, Hidehiko Makino, Yumiko Wada, Ayaka Yoshikawa, Takayuki Fujii, Wataru Yamamoto, Atsushi Kumanogoh, Seiji Okada, Ken Nakata, Kosuke Ebina |
| 発行年月 | 2026/05 |
| 概要 | OBJECTIVE:Herpes zoster (HZ) is a common adverse event associated with Janus kinase inhibitors (JAKi); however, direct comparisons using real-world data are lacking, which we aimed to clarify.METHODS:We retrospectively analyzed data from the multicenter ANSWER cohort, including 1,096 treatment courses from 765 patients with RA (84.1% female; mean age, 63.9 years; mean follow-up, 18.2 months) who initiated treatment with tofacitinib, baricitinib, peficitinib, upadacitinib, or filgotinib. Incidence rates (IRs) of HZ were calculated per 100 patient-years using exact Poisson method. Time-to-event and treatment retention analysis were performed using Kaplan-Meier methods, and hazard ratios (HRs) were estimated using Cox proportional hazards models adjusted for patient characteristics.RESULTS:During follow-up, HZ occurred in 88 treatment courses. The IRs per 100 person-years were 5.84 for tofacitinib, 6.21 for baricitinib, 3.79 for peficitinib, 7.38 for upadacitinib, and 1.73 for filgotinib. In the adjusted Cox model, filgotinib (reference) was associated with a significantly lower hazard of HZ compared with tofacitinib (HR, 7.68; 95% CI, 1.71-34.6; p = 0.008), baricitinib (HR, 6.35; 95% CI, 1.48-27.1; p = 0.013), and upadacitinib (HR, 4.75; 95% CI, 1.11-20.3; p = 0.036), whereas no significant differences were observed in treatment retention. Patient-related variables, including age, sex, prior HZ, and vaccination history, were not significantly associated with HZ risk.CONCLUSION:Filgotinib showed a lower observed risk of HZ compared with tofacitinib, baricitinib, and upadacitinib. Given the limited number of events and observational design, further large-scale studies with longer follow-up are warranted to confirm these findings. |
| DOI | 10.1016/j.jbspin.2026.106080 |
| PMID | 42202903 |